Free CE-accredited Webinar for Nurse Practitioners!
Diagnostic and Therapeutic Options in Binge Eating Disorder – The Role of the Nurse Practitioner
Tuesday, October 24 — 12:00 pm and 6:00 pm EDT!
Wendy L. Wright, MS, ANP-BC, FNP-BC, FAANP, FAAN
Adult/Family Nurse Practitioner
Wright & Associates Family Healthcare, PLLC
Amherst, New Hampshire
Binge eating disorder (BED) is the most frequently diagnosed eating disorder that has its own medical and psychiatric comorbidities and has high socio-economic impact due to reduced quality of life and increased health service use. This webinar will focus on how the specific features of BED can be identified at baseline and how to screen patients. It will also provide strategies for nurse practitioners to appropriately select among (or combine) behavioral, psychotherapeutic and pharmacotherapeutic modalities to optimally treat and manage their patients.
Upon completion of this educational activity, participants will be able to:
Define the components of the clinical diagnosis of binge eating disorder (BED) as an eating disorder
Describe the options for treating BED, how to screen patients with multiple psychological co-morbidities in the diagnosis of BED, and how to establish a baseline assessment.
Identify the pharmacologic basis for the treatment of BED.
Describe the non-pharmacologic treatments available to patients with BED.
Explore the therapeutic treatments available to patients with BED.
This educational activity is supported by an independent medical educational grant from Shire.
Targeted Audience: Nurse Practitioners who work in the primary care and specialty settings who consult with patients with binge eating disorder.
Registration Fee: There is no fee to participate in this activity.
Length of Webinar: 1 hour
Instructions for Obtaining Credit:
To receive credit, participants must complete the pre-assessment polling questions, view the webinar in its entirety, and complete the post-assessment questions and activity evaluation form. All participants must request credit before November 24. 2017. CE credit will not be issued after this date.
This educational activity has been a joint collaboration between Dannemiller™ and PER®
Dannemiller is approved as a provider of nurse practitioner continuing education by the American Association of Nurse Practitioners: AANP Provider Number 090419. This program has been approved for 1.0 contact hours of continuing education (which includes 0.0 hours of pharmacology).
In the event you have questions about this activity or are unable to retrieve the certificate, please e-mail firstname.lastname@example.org and a certificate will be emailed within 2 weeks.
Disclosure of Conflicts of Interest
Dannemiller and PER®
requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
Faculty disclosures will be provided prior to the presentation.
The following contributors have no relevant financial relationships with commercial interests to disclose.
Pharmacy Times Continuing Education™
—David Heckard; Maryjo Dixon, RPh; Dipti Desai, PharmD; and Donna Fausak;
—Gloria Herrera, RN, MSN, FNP-BC and Jennifer Hodge
Dannemiller and PER®
strive to provide the highest level of service. However, unforeseen circumstances may necessitate the rescheduling or cancellation of live events, including, but not limited to, webinars, hosted by PER®
reserves the right to cancel an event without notice. PER®
will not be responsible for any expenditure incurred due to the cancellation.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Dannemiller and PER®
do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Required: Windows® 7, Vista, XP, 2003 Server or 2000
Required: Mac OS® X 10.4.11 (Tiger®) or newer
For questions about this Internet CPE activity, please contact: email@example.com